Lessons from building an AI-driven contracting platform

Turquoise Health CEO Chris Severn and CTO Adam Geitgey share what they learned building a real AI-driven contracting platform used by major health systems — what worked, what didn't, and what AI can actually fix in managed care contract administration today. See it in action.

How device manufacturers can leverage price transparency data ft. Boston Scientific

Boston Scientific joins Turquoise Health to show device manufacturers how to turn public price transparency files into a competitive advantage — finding negotiated rates, addressing data quality challenges, and building decision-ready reimbursement insights. See it in action.

The past, present, and future of drug rates

Turquoise's Wayne Laun and Chris O'Dell trace how price transparency legislation has reshaped drug reimbursement — covering how providers and manufacturers are using drug rate data today, and what the latest executive order means for drug price transparency going forward. Explore the data.

Behind the report: 2025 drug reimbursement trends explained live

Turquoise Health and ZS unpack the 2025 drug reimbursement trends report live — explaining why some providers are reimbursed at 1–2× ASP and others at 10×, and what manufacturers can do with price transparency data to anticipate and respond to reimbursement dynamics. Explore the data.